|
1
|
Schaff LR and Mellinghoff IK: Glioblastoma
and other primary brain malignancies in adults: A review. JAMA.
329:5742023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312.
2020.PubMed/NCBI
|
|
3
|
Stupp R, Weller M, Belanger K, Bogdahn U,
Ludwin SK, Lacombe D and Mirimanoff RO: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alves ALV, Gomes INF, Carloni AC, Rosa MN,
da Silva LS, Evangelista AF, Reis RM and Silva VAO: Role of
glioblastoma stem cells in cancer therapeutic resistance: A
perspective on antineoplastic agents from natural sources and
chemical derivatives. Stem Cell Res Ther. 12:2062021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang P, Xia Q, Liu L, Li S and Dong L:
Current opinion on molecular characterization for GBM
classification in guiding clinical diagnosis, prognosis, and
therapy. Front Mol Biosci. 7:5627982020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sottoriva A, Spiteri I, Piccirillo SG,
Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C and Tavaré
S: Intratumor heterogeneity in human glioblastoma reflects cancer
evolutionary dynamics. Proc Natl Acad Sci. 110:4009–4014. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dirkse A, Golebiewska A, Buder T, Nazarov
PV, Muller A, Poovathingal S, Brons NHC, Leite S, Sauvageot N,
Sarkisjan D, et al: Stem cell-associated heterogeneity in
Glioblastoma results from intrinsic tumor plasticity shaped by the
microenvironment. Nat Commun. 10:17872019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barthel L, Hadamitzky M, Dammann P,
Schedlowski M, Sure U, Thakur BK and Hetze S: Glioma: Molecular
signature and crossroads with tumor microenvironment. Cancer
Metastasis Rev. 41:53–75. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gieryng A, Pszczolkowska D, Walentynowicz
KA, Rajan WD and Kaminska B: Immune microenvironment of gliomas.
Lab Invest. 97:498–518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Corsaro A, Tremonti B, Bajetto A, Barbieri
F, Thellung S and Florio T: Chemokine signaling in tumors:
Potential role of CXC chemokines and their receptors as
glioblastoma therapeutic targets. Expert Opin Ther Targets.
28:937–952. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai Y, Yu C, Zhou L, Cheng L, Ni H and
Liang W: Chemokine receptor CXCR4 interacts with nuclear receptor
Nur77 and promote glioma invasion and progression. Brain Res.
1822:1486472024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Detchou D and Barrie U: Interleukin 6 and
cancer resistance in glioblastoma multiforme. Neurosurg Rev.
47:5412024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Narasimhappagari J, Liu L, Balasubramaniam
M, Ayyadevara S, Aboud O and Griffin WST: The seminal role of the
proinflammatory cytokine IL-1β and its signaling cascade in
glioblastoma pathogenesis and the therapeutic effect of
Interleukin-1β receptor antagonist (IL-1RA) and tolcapone. Int J
Mol Sci. 26:68932025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mentlein R, Hattermann K and Held-Feindt
J: Migration, metastasis, and more: The role of chemokines in the
proliferation, spreading, and metastasis of tumors. Trends in Stem
Cell Proliferation and Cancer Research. Resende RR and Ulrich H:
Springer Netherlands; Dordrecht: pp. 339–358. 2013, View Article : Google Scholar
|
|
16
|
Klein E, Hau AC, Oudin A, Golebiewska A
and Niclou SP: Glioblastoma organoids: Pre-Clinical applications
and challenges in the context of immunotherapy. Front Oncol.
10:6041212020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pernik MN, Bird CE, Traylor JI, Shi DD,
Richardson TE, McBrayer SK and Abdullah KG: Patient-derived cancer
organoids for precision oncology treatment. J Pers Med. 11:4232021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Jin M, Zhao J, Chen J and Jin W:
Organoid models of glioblastoma: Advances, applications and
challenges. Am J Cancer Res. 10:2242–2257. 2020.PubMed/NCBI
|
|
19
|
Xu X, Li L, Luo L, Shu L, Si X, Chen Z,
Xia W, Huang J, Liu Y, Shao A and Ke Y: Opportunities and
challenges of glioma organoids. Cell Commun Signal. 19:1022021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pawlowski KD, Duffy JT, Babak MV and
Balyasnikova IV: Modeling glioblastoma complexity with organoids
for personalized treatments. Trends Mol Med. 29:282–296. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Sun Y, Zhang DY, Ming G and Song
H: Glioblastoma modeling with 3D organoids: Progress and
challenges. Oxf Open Neurosci. 2:kvad0082023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu C, Yuan X, Hou P, Li Z, Wang C, Fang C
and Tan Y: Development of glioblastoma organoids and their
applications in personalized therapy. Cancer Biol Med. 20:353–368.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lancaster MA, Renner M, Martin CA, Wenzel
D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP and
Knoblich JA: Cerebral organoids model human brain development and
microcephaly. Nature. 501:373–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soubéran A and Tchoghandjian A: Practical
review on preclinical human 3D glioblastoma models: Advances and
challenges for clinical translation. Cancers. 12:23472020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hubert CG, Rivera M, Spangler LC, Wu Q,
Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE and Rich JN: A
Three-dimensional organoid culture system derived from human
glioblastomas recapitulates the hypoxic gradients and cancer stem
cell heterogeneity of tumors found in vivo. Cancer Res.
76:2465–2477. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jacob F, Salinas RD, Zhang DY, Nguyen PTT,
Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, et
al: A Patient-derived glioblastoma organoid model and biobank
recapitulates Inter- and Intra-tumoral heterogeneity. Cell.
180:188–204.e22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hellmold D, Johanning L, Clüver J, Holler
J, Schröder NO, Bayler F, Ahmeti H, Kubelt-Kwamin C, Wieker S,
Helmers AK, et al: Effect of focused ultrasound-induced mechanical
ablation on stemness and dormancy properties of
residual/peri-focally localized glioblastoma cells. Neurooncol Adv.
7:vdaf1842025.PubMed/NCBI
|
|
28
|
Qiang J, Wei Z, Xiao-guang Q and Wei Y:
Gene expression profiling reveals Ki-67 associated proliferation
signature in human glioblastoma. Chin Med J (Engl). 124:2584–2588.
2022.PubMed/NCBI
|
|
29
|
Jung CS, Foerch C, Schanzer A, Heck A,
Plate KH, Seifert V, Steinmetz H, Raabe A and Sitzer M: Serum GFAP
is a diagnostic marker for glioblastoma multiforme. Brain.
130:3336–3341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Zhang L, Zhang IY, Chen X, Da
Fonseca A, Wu S, Ren H, Badie S, Sadeghi S, Ouyang M, et al: S100B
promotes glioma growth through chemoattraction of Myeloid-derived
macrophages. Clin Cancer Res. 19:3764–3775. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang P, Zhao L, Gong S, Xiong S, Wang J,
Zou D, Pan J, Deng Y, Yan Q, Wu N and Liao B: HIF1α/HIF2α-Sox2/Klf4
promotes the malignant progression of glioblastoma via the
EGFR-PI3K/AKT signalling pathway with positive feedback under
hypoxia. Cell Death Dis. 12:3122021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Polat B, Wohlleben G, Kosmala R, Lisowski
D, Mantel F, Lewitzki V, Löhr M, Blum R, Herud P, Flentje M and
Monoranu CM: Differences in stem cell marker and osteopontin
expression in primary and recurrent glioblastoma. Cancer Cell Int.
22:872022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Noorani I, Petty G, Grundy PL, Sharpe G,
Willaime-Morawek S, Harris S, Thomas GJ, Nicoll JA and Boche D:
Novel association between microglia and stem cells in human
gliomas: A contributor to tumour proliferation? J Pathol Clin Res.
1:67–75. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kmiecik J, Poli A, Brons NH, Waha A, Eide
GE, Enger PØ, Zimmer J and Chekenya M: Elevated CD3+ and CD8+
tumor-infiltrating immune cells correlate with prolonged survival
in glioblastoma patients despite integrated immunosuppressive
mechanisms in the tumor microenvironment and at the systemic level.
J Neuroimmunol. 264:71–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu-Emerson C, Snuderl M, Kirkpatrick ND,
Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda
DG, et al: Increase in tumor-associated macrophages after
antiangiogenic therapy is associated with poor survival among
patients with recurrent glioblastoma. Neuro Oncol. 15:1079–1087.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mei X, Chen YS, Chen FR, Xi SY and Chen
ZP: Glioblastoma stem cell differentiation into endothelial cells
evidenced through live-cell imaging. Neuro-Oncol. 19:1109–1118.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang S, Chen C, Li J, Xu X, Chen W and Li
F: The CXCL12/ CXCR4 axis confers temozolomide resistance to human
glioblastoma cells via up-regulation of FOXM1. J Neurol Sci.
414:1168372020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hattermann K, Held-Feindt J, Lucius R,
Müerköster SS, Penfold MET, Schall TJ and Mentlein R: The chemokine
receptor CXCR7 is highly expressed in human glioma cells and
mediates antiapoptotic effects. Cancer Res. 70:3299–3308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng L, Zheng W, Dong X, Liu J, Zhu C, Lu
D, Zhang J, Song L, Wang Y and Deng D: Chemokine receptor CXCR7 is
an independent prognostic biomarker in glioblastoma. Cancer
Biomark. 20:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Adamski V, Mentlein R, Lucius R, Synowitz
M, Held-Feindt J and Hattermann K: The chemokine receptor CXCR6
evokes reverse signaling via the transmembrane chemokine CXCL16.
Int J Mol Sci. 18:14682017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chia TY, Billingham LK, Boland L, Katz JL,
Arrieta VA, Shireman J, Rosas AL, DeLay SL, Zillinger K, Geng Y, et
al: The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity
in a spatiotemporal context. Front Immunol. 14:13312872024.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee S, Latha K, Manyam G, Yang Y, Rao A
and Rao G: Role of CX3CR1 signaling in malignant transformation of
gliomas. Neuro Oncol. 22:1463–1473. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hattermann K, Held-Feindt J, Ludwig A and
Mentlein R: The CXCL16-CXCR6 chemokine axis in glial tumors. J
Neuroimmunol. 260:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ehtesham M, Mapara KY, Stevenson CB and
Thompson RC: CXCR4 mediates the proliferation of glioblastoma
progenitor cells. Cancer Lett. 274:305–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sciumè G, Soriani A, Piccoli M, Frati L,
Santoni A and Bernardini G: CX3CR1/CX3CL1 axis negatively controls
glioma cell invasion and is modulated by transforming growth
factor-beta1. Neuro Oncol. 12:701–710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hattermann K, Sebens S, Helm O, Schmitt
AD, Mentlein R, Mehdorn HM and Held-Feindt J: Chemokine expression
profile of freshly isolated human glioblastoma-associated
macrophages/microglia. Oncol Rep. 32:270–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ludwig A, Schulte A, Schnack C, Hundhausen
C, Reiss K, Brodway N, Held-Feindt J and Mentlein R: Enhanced
expression and shedding of the transmembrane chemokine CXCL16 by
reactive astrocytes and glioma cells. J Neurochem. 93:1293–1303.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kai K, Komohara Y, Esumi S, Fujiwara Y,
Yamamoto T, Uekawa K, Ohta K, Takezaki T, Kuroda J, Shinojima N, et
al: Macrophage/microglia-derived IL-1β induces glioblastoma growth
via the STAT3/NF-κB pathway. Hum Cell. 35:226–237. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim S, Kim KH, Jung H, Jeong EO, Lee HJ,
Kwon J, Kwon HJ, Choi SW, Koh HS and Kim SH: Elevated serum IL-6 as
a negative prognostic biomarker in glioblastoma: Integrating
bioinformatics and clinical validation. J Cancer. 16:802–811. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen R, Nishimura MC, Bumbaca SM,
Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour
LL and Rivers CS: A hierarchy of Self-renewing Tumor-initiating
cell types in glioblastoma. Cancer Cell. 17:362–375. 2010.
View Article : Google Scholar : PubMed/NCBI
|
